Cancer cells reprogram their metabolism while muting the immune system's alarm bells
In the quiet architecture of the body's own tissue, breast cancer has long concealed its most dangerous maneuver — the migration to lymph nodes. A new study from researchers in China has now illuminated the cellular choreography behind this escape, revealing how cancer cells rewrite their own metabolism, recruit immune cells as unwitting collaborators, and construct a sanctuary where the body's defenses cannot reach them. Analyzing more than 360,000 individual cells, the work offers not only a map of how metastasis unfolds, but a set of coordinates for where it might be interrupted.
- Breast cancer's spread to lymph nodes — one of the deadliest turning points in the disease — has long resisted clear explanation, leaving clinicians without precise targets to intervene.
- A population of early disseminated cancer cells has been caught in the act: rewiring their energy systems to thrive in hostile conditions while simultaneously silencing the immune signals that would expose them.
- M2-type macrophages, co-opted by the tumor environment, flood the tissue with immunosuppressive molecules that shield cancer cells and accelerate their transformation into more dangerous forms.
- Spatial mapping pinpointed exactly where these cellular conspiracies occur — at the invasion front of lymph node tissue — giving researchers a geographic as well as molecular target.
- The study's three-way framework — cancer cell, metabolism, immunity — now offers a blueprint for therapies that could disrupt metastasis at multiple points in the chain rather than attacking cancer cells alone.
Researchers have charted the cellular machinery behind one of breast cancer's most lethal moves — its spread into lymph nodes — uncovering a coordinated system in which cancer cells, immune cells, and surrounding tissue conspire to defeat the body's defenses. The study, published in The American Journal of Pathology and led by teams at two Nanjing universities in China, drew on over 360,000 cells from 78 paired samples of primary tumors and their lymph node metastases.
At the center of the findings is a cell population the researchers call early disseminated cancer cells, or EDCs. These cells have already begun their journey outward and have undergone a striking transformation: they shift toward glycolysis to sustain themselves in low-oxygen environments and, simultaneously, suppress the immune system's ability to detect and destroy them. The combination of metabolic self-sufficiency and immune evasion gives them a decisive edge in hostile territory.
They do not operate in isolation. A subset of macrophages — immune cells that have been turned to the tumor's advantage — secrete signaling molecules including CCL22 and CXCL12, creating a chemically immunosuppressive zone where cancer cells can proliferate unchallenged. Spatial transcriptomics confirmed that these interactions concentrate at the invasion front of lymph node tissue, where cancer is actively breaching new ground.
Lead investigator Li Guo described the work as revealing unprecedented insight into cellular communication within the metastatic environment. Co-lead Tingming Liang identified the three-way interaction between cancer cells, metabolism, and immunity as both the core mechanism of lymph node metastasis and its most promising therapeutic vulnerability. Future treatments, the researchers suggest, might target the enabling macrophages, block the cytokines they release, or disrupt the metabolic pathways that allow EDCs to survive — offering multiple points of intervention in a process that, left unchecked, often determines whether a patient lives or dies.
Researchers have mapped the cellular machinery that allows breast cancer to spread to lymph nodes, revealing a coordinated system in which cancer cells reprogram their metabolism, immune cells switch sides, and the tissue environment becomes hostile to the body's defenses. The work, published in The American Journal of Pathology, analyzed over 360,000 cells from 78 paired samples of primary breast tumors and their lymph node metastases, constructing what the team calls a "cell-metabolism-immunity" landscape of how cancer escapes.
Breast cancer kills more women than any cancer except lung cancer, and lymph node involvement is one of the strongest predictors of poor outcomes. Yet the precise mechanisms that allow cancer cells to establish themselves in lymph nodes have remained opaque. The new study, led by researchers at Nanjing University of Posts and Telecommunications and Nanjing Normal University in China, used two complementary technologies to see what was happening: single-cell RNA sequencing, which reads the genetic activity of individual cells, and spatial transcriptomics, which maps that activity back onto the tissue itself so researchers can see which cells are talking to which.
The team identified ten major cell types in the metastatic environment and zeroed in on a particularly troubling population: early disseminated cancer cells, or EDCs. These are cancer cells that have begun their journey to distant sites and have undergone a metabolic transformation. They activate pathways that allow them to survive in low-oxygen conditions and shift toward glycolysis, a primitive but efficient way to generate energy. At the same time, they actively suppress the immune system's ability to recognize and kill them. This dual strategy—becoming metabolically self-sufficient while muting the alarm bells—gives them a decisive advantage.
But the EDCs do not act alone. The research revealed a three-way conversation between cancer cells, immune cells called macrophages, and the structural cells that make up the tissue. Specifically, a subset of macrophages known as M2-type begin secreting chemical signals like CCL22 and CXCL12. These molecules create an immunosuppressive microenvironment—essentially a safe harbor where cancer cells can grow without triggering an immune response. The same signals also push the EDCs further along the path toward malignancy. Spatial mapping confirmed that these interactions cluster in specific regions of the lymph node tissue, particularly at the invasion front where cancer cells are actively penetrating.
Li Guo, the lead investigator, described the finding as revealing "unprecedented insights into the dynamic changes and cellular communication patterns within the metastatic microenvironment." Co-lead investigator Tingming Liang emphasized that "this systemic interaction between cancer cells, metabolism, and immunity is the core mechanism of lymph node metastasis and a potential therapeutic target." The implication is clear: if researchers can disrupt any link in this chain—the metabolic reprogramming, the immune suppression, or the cellular crosstalk—they might be able to stop metastasis before it takes hold.
The findings provide a molecular foundation for developing new drugs. Rather than attacking cancer cells alone, future therapies might target the macrophages that enable them, or block the specific cytokines they secrete, or interfere with the metabolic pathways that allow EDCs to survive. The work also suggests that understanding the spatial organization of these interactions—not just which cells are present, but where they are and how close they are to one another—will be essential for designing effective treatments. For patients with breast cancer, the difference between stopping metastasis and allowing it to spread is often the difference between survival and death.
Citações Notáveis
This systemic interaction between cancer cells, metabolism, and immunity is the core mechanism of lymph node metastasis and a potential therapeutic target.— Tingming Liang, co-lead investigator, Nanjing Normal University
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that researchers can now see these cells in their original location, rather than just knowing they exist?
Because proximity is everything in cancer. A macrophage sitting next to a cancer cell can whisper to it—literally, through chemical signals—in ways that a macrophage across the tissue cannot. Spatial transcriptomics shows you the actual neighborhoods where metastasis happens. You can see the invasion front, the boundary where cancer is pushing into healthy tissue, and understand what's enabling that push.
These early disseminated cancer cells sound like scouts. Are they different from the cancer cells in the original tumor?
Yes, fundamentally. They've undergone a metabolic shift—they're running on different fuel, adapted to survive in harsh conditions. They're also actively suppressing immunity. It's not that they're just tougher versions of the original cells; they're cells that have learned to hide and to make their environment hostile to the immune system.
The macrophages are supposed to be part of the immune system. How do they end up helping cancer?
That's the dark turn. Macrophages are scavengers by nature—they clean up debris, respond to inflammation. But in the tumor microenvironment, cancer cells reprogram them. The M2-type macrophages start secreting immunosuppressive signals instead of inflammatory ones. They become enablers rather than defenders.
If you could block those signals—the CCL22 and CXCL12—would that stop metastasis?
That's the hope, and it's why this work matters clinically. But it's not simple. You'd need to block them specifically in the tumor microenvironment without disrupting normal immune function elsewhere. That's the challenge ahead.
How many patients could this eventually help?
Breast cancer affects millions of women globally. Lymph node involvement changes treatment and prognosis dramatically. If you could prevent or slow metastasis, you're potentially changing outcomes for a huge population. But this is foundational research. The drugs don't exist yet.